

# FUNDING ANNOUNCEMENT

## PARIS, OCTOBER 2014

### **MOVEMBER FOUNDATION INVESTS €1.5 MILLION IN FRENCH-SWISS CLINICAL TRIAL DESIGNED TO TACKLE THE LETHAL PROGRESSION OF PROSTATE CANCER.**

The Movember Foundation, the leading global organization committed to changing the face of men's health, today announced plans to invest €1.5 million funding to support a prostate cancer clinical trial in France and Switzerland. The planned funding, the Movember Foundation's most significant investment to date in both countries, will support a clinical trial that has the potential to slow or stop the lethal progression of prostate cancer.

The funding will support a clinical trial that demonstrates innovative treatment methods that have the potential to be available both quickly and affordably to men with advanced prostate cancer. The trial will enable the French prostate cancer research community to collaborate with their Swiss colleagues to make a significant impact on the clinical management of advanced prostate cancer.

Paul Villanti, Executive Director, Programmes for the Movember Foundation said: "We only have one definition of success: finding breakthrough solutions that produce tangible improvements in the lives of those dealing with prostate cancer. We believe this significant new investment in the French and Swiss prostate cancer research communities will strongly support this by harnessing the scientific strengths in those markets and fostering a collaborative approach to research. This investment has been made possible by the passionate Mo Bros and Mo Sistas of France and Switzerland and their fundraising efforts – were looking forward to seeing Mo's signing up to the campaign across both countries again this Movember."

In keeping with the Movember Foundation's approach to research, the funding will support at least two institutions from both France and Switzerland working collaboratively on the trial. This multi-institutional approach to research brings together the best scientific and clinical minds in the countries, to collaboratively tackle and solve the critical challenges confronting men with advanced prostate cancer.

Institutions will be invited to apply for funding in December, and it's anticipated that the trial will be delivered and evaluated over four years. The trial is being funded by the proceeds of the 2013 and 2014 Movember campaigns in France and Switzerland.

In addition to the clinical trial funding announcement, the Movember Foundation will be continuing to fund French researchers taking part in Movember's Global Action Plan, which is an international research collaboration initiative that is accelerating outcomes by providing researchers from around the world the opportunity to work together on specific research projects. French researchers at the University of Lille have been awarded €161,000 for their contribution to the GAP3 project. By integrating clinical, imaging and biomarker data in a global central database, GAP3 will unite the world's leading research and clinical groups focusing on prostate cancer Active Surveillance, to optimise the therapeutic guidelines for men diagnosed with low risk prostate cancer. The ultimate aim is to reduce the side effects associated with over-treatment and optimise therapy for those men who truly do need to be treated.

